MarketLens
Sign Up

Thermo Fisher Scientific's C-Suite Selling Tests a Fully-Priced Growth Story

2 months ago
SHARE THIS ON:

Thermo Fisher Scientific's C-Suite Selling Tests a Fully-Priced Growth Story

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 months ago

TMO DCF Analysis: Intrinsic Value $491 vs Price $588

Thermo Fisher Scientific's DCF analysis implies intrinsic value of $491 per share, 16.5% below its $588 price, after a mixed recent performance. The gap suggests potential downside if market assumptio...
Stock News•2 months ago

Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg

Thermo Fisher Scientific completed the sale of its microbiology business to Astorg for ~$1.075 billion in cash and a $50 million seller note, after the divestiture of its antimicrobial susceptibility ...
Stock News•2 months ago

How Thermo Fisher Is Riding Bioproduction and AI-Led Growth Trends

Thermo Fisher is expanding bioproduction, AI tools, and clinical data capabilities to drive growth, though execution remains key amid intensifying competition.

Breaking News

View All →

No topics available at the moment

Top Headlines

View More →
Stock News•54 minutes ago

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Alphabet Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GOOGL, GOOG

Stock News•1 hour ago

Why the Market Dipped But Meta Platforms (META) Gained Today

Stock News•1 hour ago

Nvidia in 5 Years: Where the Stock Could Be Headed

Stock News•2 hours ago

UK finance minister Healey to target online marketplaces in tax crackdown, The Times reports

Stock News•2 hours ago

Character.AI owes Google and Big Law firms nearly $7M, court filings show